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Abstract
Increased risk and severity of idiopathic pulmonary arterial hypertension (iPAH) is associated with elevated estradiol in men and
postmenopausal women. Pulmonary arteries synthesise estradiol via aromatase and metabolise it via CYP1B1 to mitogenic
metabolites; SNPs in aromatase and CYP1B1 have been associated with PAH. This suggests that estradiol metabolism could be
altered in iPAH. This proof-of-concept study profiles estradiol and several metabolites of estradiol simultaneously in serum from
iPAH patients and controls. We show that the estradiol and metabolite profile is altered in iPAH and that 16-hydroxyestrone and
16-hydroxyestradiol accumulate in iPAH patients with 16-hydroxyestrone levels relating to disease severity.
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Introduction
Increased risk and severity of idiopathic pulmonary arterial
hypertension (iPAH) is associated with elevated plasma
estradiol in both men and postmenopausal women,1,2 sug-
gesting that estradiol is not ovarian-derived. Aromatase is
responsible for the synthesis of estradiol. Remodeled pul-
monary arteries, lesions, and human pulmonary artery
smooth muscle cells (hPASMCs) from pulmonary arterial
hypertension patients have high levels of aromatase.3
Cytochrome P450 Family 1 Subfamily B Member 1
(CYP1B1) can convert estradiol to mitogenic 16-hydroxyes-
trogens and this enzyme is over-expressed in diseased pul-
monary arteries from pulmonary arterial hypertension
(PAH) patients.4 Existing assays have not been sensitive or
specific enough to detect levels of many estradiol metabol-
ites in PAH patient blood. Using a newly developed liquid
chromatography tandem mass spectrometry (LC-MS/MS)
assay,5 here we investigate the profile of several estradiol
metabolites in iPAH patients.
Methods
Serum from 22 subjects with iPAH (12 males, 10 females)
and 34 healthy control subjects (17 males, 17 females)
were analyzed by LC-MS/MS for estrone (E1), 17a-
estradiol (17aE2), 17-estradiol (E2), 16-hydroxyestrone
(16OHE1), 16-hydroxyestradiol (16OHE2), 2-methoxyes-
trone (2MeOE1), 4-methoxyestrone (4MeOE1), 2-methox-
yestradiol (2MeOE2), and 4-methoxyestradiol (4MeOE2).5
Data were compared by a Mann–Whitney U test with asso-
ciations assessed using Pearson’s correlations. Values below
the confirmed limit of quantification (LOQ) were imputed as
the LOQ (2 pg/mL E1, E2, 16OHE2, 2MeOE1, and 6 pg/mL
16OHE1).
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To determine if 16OHE2 was present at bioactive
concentrations, proliferation was studied in hPASMCs and
cell migration was studied in human blood outgrowth
endothelial cells (BOECs). hPASMCs were isolated from
distal pulmonary arteries (0.3–1mm diameter) from
macroscopically normal controls or patients undergoing
lung transplantation. BOECs were isolated from PAH
patients as described previously6 with cells cultured as
describedpreviously.7Thepatientsweremale and female (her-
itable PAH/iPAH). Cells were stimulated with 16OHE2 fol-
lowing preliminary concentration-response analysis (10 nM
hPASMCs and 1 nM BOECs) for 48 h in phenol red-free
media. Cell counts and cell migration (Corning Transwell
inserts) were assessed using a Countess II FL cell counter
(Life Technologies, UK). A student’s t-test was applied for
comparison of 16OHE2 vs vehicle-treated cells for each
group.
Results
E1 was decreased in serum of female iPAH patients whilst
16OHE2 was increased. E1, E2, and 16OHE1 were elevated
in male iPAH patients (Table 1). Comparing males and
females, E1 was higher in female controls compared with
male controls (p¼ 0.01). In iPAH, E1 was higher in males
than females (p¼ 0.03).
In female iPAH patients, increased E1 was associated
with increasing pulmonary artery wedge pressure (PAWP)
(R2¼ 0.5, ¼ 0.7, p¼ 0.03), decreased E2 was associated
with increasing age (R2¼ 0.7, ¼ –0.8, p¼ 0.02), and
increasing E2 with increasing PAWP (R2¼ 0.6, ¼ 0.6,
p¼ 0.05) while increased 16OHE1 correlated with a reduc-
tion of cardiac output (R2¼ 0.7, ¼ –0.6, p¼ 0.01). In male
iPAH, increased E2 was associated with increased PAWP
(R2¼ 0.5, ¼ 0.6, p¼ 0.02) while increased E1 and E2 asso-
ciated with increasing BNP levels (R2¼ 0.6, ¼ 0.8, p¼ 0.01
and R2¼ 0.4, ¼ 0.6, p¼ 0.04).
16OHE2 caused proliferation of hPASMCs from female
PAH patients (by 63%) but not controls (male or female)
(Fig. 1a–c). 16OHE2 caused increased migration of BOECs
from PAH patients, both in males (by 55%) and females
(by 67%) (Fig. 1d).
Discussion
This study is the first to simultaneously quantify several
estrogens in controls and PAH patients as our methodo-
logical paper measured levels in pooled plasma samples.5
LC-MS/MS allowed discrimination between isomers of E2
and its bioactive metabolites such as 16OHE1, 16OHE2,
and methoxyestrogens. Increased 16-hydroxylation of E1/
E2 promotes formation of proliferative metabolites and we
identified accumulation of 16OHE2 in female iPAH patient
serum for the first time. We confirmed increased levels of
16OHE1 in patients which had been suggested by previous
studies.8,9 In female iPAH, 16OHE2 was also increased.
There was increased E1 and E2 levels in male iPAH patients,
consistent with a previous study using immunoassay detec-
tion.1 The E2 concentrations we determined here were lower
compared with previous studies determined using immuno-
assays. This is consistent with immunoassays being limited
by cross-reactivity and over-estimation of E2 levels com-
pared with LC-MS/MS.10
Aromatase andCYP1B1 are increased in PAHpatient pul-
monary arteries and pulmonary vascular lesions.3,4 Increased
aromatase activity may account for increased plasma E2 in
men and post-menopausal women with iPAH.1,2 In female
iPAH, there was a decrease in E1 with no change in E2. The
change in E1 may reflect an increased conversion to 16OHEs
via CYP enzymes as reflected by increased 16OHE1 and
16OHE2 in these patients. Where there is a decrease in E1
with no change in E2, this could also be due to the increased
metabolism of E2. Baird et al. recently demonstrated that E2
levels are elevated in post-menopausal iPAH female patients
compared with controls; however, E2 levels from controls in
that study were 5–7 pg/mL, commensurate with post-meno-
pause levels.2 The majority of females in this current study
were pre-menopausal, with sampling not routinely timed to
considermenstrual cycle, andmeanE2 concentrations in con-
trols and patients were 34 pg/mL. Hence, it is perhaps unli-
kely that a further increase would be expected in this patient
cohort. Future clinical studies could consider blood sampling
from pre-menopausal women at the same stage of the men-
strual cycle.3
As 16OHE1 can be derived directly from E1 and
male patients have higher E1, this may also contribute to
the elevated 16OHE1 in these patients. Consistent with
increased 16OHEs observed in iPAH patients, polymorph-
isms in CYP1B1 are observed in PAH patients associated
with functional differences in 16-hydroxylation, cancer
risk, and E2-mediated carcinogenicity.11,12 Conversion
of E2 to 16OHE1 by CYP1B1 may contribute to the
pathogenesis of experimental pulmonary hypertension
and cause proliferation of hPASMCs via increased oxidative
stress.7,8
We have already demonstrated that 16OHE1 can cause
proliferation of both male and female hPASMCs and male
mouse PASMCs at concentrations observed in plasma.4,7,13
16OHE1 acts through the ERa receptor in hPASMCs7,14
and indeed we have shown that ERa receptors are more
highly expressed in female PAH hPASMCs.15 This is con-
sistent with female hPASMCs being more proliferative to
E2, also due to decreased basal bone morphogenetic protein
receptor II (BMPRII) signaling in female hPASMCs.16
16OHE2 is a novel metabolite with unknown effects that
was increased in the serum from female iPAH patients com-
pared with controls. This could also be due to altered
CYP1B1-mediated 16-hydroxlation.4,13 16OHE2 is an E2-
receptor agonist, capable of cellular proliferation associated
with cancer risk and E2-mediated carcinogenicity.12
Consistent with this, we now show that, at a pathophysio-
logical concentration, 16OHE2 can also induce proliferation
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in female human PAH PASMCs with no effect in female or
male control PASMCs where ERa expression is not so high.
However, we show that 16OHE2 increases cell migration in
both male and female PAH BOECs. As 16OHE1 has been
shown to act as a ‘‘second hit’’ to uncover a pulmonary
hypertensive phenotype in BMPRII mutant male and
female mice,9 this suggests that both 16OHE1 and
16OHE2 may also facilitate pulmonary vascular remodeling
Table 1. Clinical characteristics and estrogen concentrations for controls vs iPAH patients.
Female controls Female iPAH P-Values Male controls Male iPAH P-Values
Subjects 17 10 17 12
Clinical characteristics
Age (y) 39.0 (31–45) 56.5 (43–61) 0.01 32.5 (27–37) 57.0 (50–62) 0.001
BMI (kgm–2) 24.9 (22–28) 29.1 (28–31) 0.06 23.8 (22–33) 32.8 (29–34) 0.07
Right atrial pressure (mmHg) 6.0 (4–10) 9.0 (7–14) 0.23
mPAP (mmHg) 55.0 (35–62) 51.5 (40–60) 0.97
Cardiac output (L/min) 5.3 (5–7) 4.6 (4–6) 0.38
PAWP (mmHg) 9.0 (8–12) 11.0 (9–16) 0.23
PVR (mmHg/lmin) 9.0 (4–13) 9.1 (4–11) 0.97
BNP (pg/mL) 76.0 (25–238) 114.0 (21–350) 0.79
Current PAH medications
ERA 3 4
PDE5 inhibitor 2 4
Epoprostenol or treprostinil 2 2
Calcium channel blocker – 1
Treatment naı¨ve – 1
Estrogen concentrations (pg/mL)
E1 34.9 (27–75) (100) 16.9 (9–34) (91) 0.02 23.6 (17–32) (100) 28.1 (24–55) (100) 0.05
E2 16.8 (10–59) (100) 7.9 (4–65) (100) 0.15 16.0 (10–21) (100) 21.3 (19–30) (100) 0.02
16OHE1 24.8 (11–38) (65) 29.8 (17–53) (91) 0.09 24.1 (19–32) (47) 79.9 (58–96) (75) 0.01
16OHE2 10.7 (9–11) (18) 14.6 (8–26) (82) 0.01 15.4 (8–18) (41) 15.9 (6–33) (67) 0.24
2MeOE1 8.4 (6–26) (41) 6.9 (6–80) (55) 1.00 10.9 (9–26) (30) 13.2 (8) –
4MeOE1 ND ND – ND ND –
2MeOE2 ND ND – ND ND –
4MeOE2 ND ND – ND ND –
<50 y estrogen
concentrations (pg/mL)
n¼ 14 n¼ 4
E1 33.7 (27–48) 39.5 (24–52) 1.00
E2 24.0 (12–64) 47.7 (25–88) 0.57
16OHE1 21.9 (12–35) 34.4 (16–52) 0.23
16OHE2 10.1 (9–11) 14.0 (10–15) 0.06
2MeOE1 8.4 (7–18) 7.0 0.64
50 y estrogen
concentrations (pg/mL)
n¼ 3 n¼ 6
E1 78.6 (56–107) 12.1 (9–19) 0.02
E2 9.6 (7–13) 4.6 (3–7) 0.26
16OHE1 37.7 29.8 (27–38) 0.38
16OHE2 16.5 21.1 (9–28) 0.26
2MeOE1 16.0 (11–21) 6.5 (6–36) 0.90
BMI: body mass index; ERA: endothelin receptor antagonist; PDE5: phosphodiesterase type 5 inhibitor; PAH: pulmonary arterial hypertension; iPAH: idiopathic
PAH; mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVR: pulmonary vascular resistance; BNP: B-type natriuretic
peptide; ND: not detected; E1: estrone; E2: 17-estradiol; 16OHE1: 16-hydroxyestrone; 16OHE2: 16-hydroxyestradiol; 2MeOE1: 2-methoxyestrone; 4MeOE1:
4-methoxyestrone; 2MeOE2: 2-methoxyestradiol; 4MeOE2: 4-methoxyestradiol.
Notes: Medication details of three female patients is unknown. Clinical characteristics and estrogen levels shown as median (Q1–Q3) (% LC-MS/MS detection).
P-values following a Mann–Whitney U test in control vs iPAH or female iPAH vs male iPAH clinical characteristics.
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in males and females by acting as a ‘‘second hit’’ to BMPRII
mutations. 16OHE2 is also produced in abundance during
pregnancy and it is interesting to speculate that it may con-
tribute to pregnancy being a risk factor for PAH.17
It should be noted that all of the medications that the
patients were prescribed are metabolized in the liver by CYP
enzymes such as CYP3A4 and CYP2C9/8 and have no
known effects on lung or liver CYP1B1 or CYP1A1 activity.
One limitation of this study is that the patients were older
than the controls. However E2 and 16OHE1 levels corre-
lated with indicators of disease severity within the patient
groups and decreased E2 was associated with increasing age
in iPAH patients. This suggests that increased E2/metabolite
levels in PAH patients are related to disease status rather
than difference in age.
The results suggest that estrogen metabolism is
altered in PAH and both 16OHE1 and 16OHE2 accumu-
late, with 16OHE1 levels relating to disease severity.
This study is limited by the small size but important as it
warrants further multi-center fully powered studies to
confirm and correlate metabolite levels with severity and
sub-groups of PAH. Future studies on CYP enzymes and
CYP1B1 inhibitors in patients with PAH may also be
valuable.
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Fig. 1. 16OHE2 stimulation increases proliferation and migration of human cells. 10 nM 16OHE2 increases proliferation in female PAH (a) with
no effect on female control (b) and male control (c) human PASMCs. 1 nM 16OHE2 increased migration of male and female BOECs derived from
PAH patients (d).
Veh: Vehicle control, Ethanol; 16OHE2: 16-hydroxyestradiol; PAH-BOECs: Blood outgrowth endothelial cell from pulmonary arterial hyperten-
sion patients.
Note: Data shown as mean SEM (n¼ 4–6) with statistics performed by comparison of 16OHE2 to veh by a Student’s t test *p< 0.05.
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